What is the efficacy and safety of DPP-4 inhibitors as add-on therapy 
for type 2 diabetes patients receiving insulin therapy with HbA1c â‰¥7%?

Please provide:
1. Summary of clinical evidence (RCTs, meta-analyses)
2. Key efficacy metrics (HbA1c reduction, fasting glucose)
3. Safety profile (hypoglycemia risk, cardiovascular safety)
4. Regulatory status (FDA, EMA approvals)
5. Comparison with other add-on therapies (GLP-1 agonists, SGLT2 inhibitors)

Cite primary sources (original papers, FDA labels, clinical guidelines).
